Back

State of the Art in antidiabetic treatment to prevent CVD

31 August 2019 (13:45 - 14:03)
Organised by:
Congress Presentation Part of: The right glucose-lowering drugs for the right patient Pharmacotherapy ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Anna Norhammar

Karolinska Institute, Stockholm (Sweden)

3 More presentations in this session

Presentation thumbnail
Albuminuria as a predictor of incident ischemic stroke and myocardial infarction in patients with type 2 diabetes but without cardiovascular disease: A Danish cohort study
Mrs M. Fangel (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Cardiovascular risk profiles and outcomes in patients with type 2 diabetes - Implications for choice of new diabetes therapies
Mrs M. Elmegaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Heart failure risk stratification and efficacy of dapagliflozin in patients with type 2 diabetes mellitus
Doctor D. Berg (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
The right glucose-lowering drugs for the right patient

The Event

Event poster

ESC Congress 2019

31 August 2019 13:45 CET
You may be interested in
thumbnail
Webinar
EAPC Webinar: Type 2 Diabetes and cardiovascular risk
12 March 2019
thumbnail
Congress Presentation
Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes
27 August 2022
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
26 August 2023
thumbnail
Congress Presentation
To improve the quality of secondary prevention strategies in diabetic patients: the BRING-UP Prevention study results
5 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources